Osimertinib After Definitive Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSCLC: Subsequent Treatments and PPO From the Phase III LAURA Study

Lung, Respiratory and Thoracic Cancer

Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study

Lung Cancer

Kato T, Dong X, Takahashi T, Soparattanapaisarn N, Geater SL, Wang CL, Arriola E, Moiseenko F, Thompson L, Grainger E, Armenteros-Monterroso E, Evans A, Bolanos A, Ramalingam SS, Lu S

doi: 10.1016/j.lungcan.2026.109486

Lung, Respiratory and Thoracic Cancer

Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy

Eur J Cancer

Arriola E, Casarini I, Özgüroğlu M, Huang M, Takahashi T, Lai X, Goto K, Maneenil K, Lee KH, Cobo M, Valdiviezo N, Evans A, Bolanos A, Huang X, Lai R, Ramalingam SS

doi: 10.1016/j.ejca.2026.116744

Lung, Respiratory and Thoracic Cancer

Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study

Lung Cancer

Ahn MJ, Lin SH, Yang CT, Lee JB, Neal JW, Okishio K, Nishino K, Smith D, Rauter M, Jimenez M, Nasirova F, Kim Y

doi: 10.1016/j.lungcan.2025.108748

ELCC 2026

Lung, Respiratory and Thoracic Cancer

The Italian ATLAS registry study: Real-world outcomes with adjuvant osimertinib in patients with resected EGFR-mutated NSCLC

WCLC 2026

Lung, Respiratory and Thoracic Cancer

Actionable Genomic Alterations in NSCLC: What is Changing in Testing and Treatment?

WCLC 2026

Lung, Respiratory and Thoracic Cancer

ADAURA: Adjuvant osimertinib provides OS benefit at eight years in patients with resected EGFR-mutated NSCLC

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

ESMO Open

Girard N, Bar J, Baas P, Chouaid C, Christoph DC, Field JK, Fietkau R, Garassino MC, Garrido Lopez P, Gregorc V, Haakensen VD, Hiltermann TJN, Kao S, McDonald F, Mornex F, Moskovitz M, Peters S, Siva S, Solomon B, Qiao Y, Anand S, Chander P, Shcherbakova T, Diaz Perez I, Filippi AR

doi: 10.1016/j.esmoop.2026.106070

Lung, Respiratory and Thoracic Cancer

Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapy

Clin Transl Radiat Oncol

Filippi AR, Bar J, Christoph DC, Field JK, Fietkau R, Garassino MC, Garrido P, Haakensen VD, Kao S, McDonald F, Mornex F, Moskovitz M, Peters S, Van Den Heuvel MM, Vercauter P, Smit HJM, Solomon B, Chander P, Qiao Y, Faria J, Girard N

doi: 10.1016/j.ctro.2026.101138

Lung, Respiratory and Thoracic Cancer

Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study

Target Oncol

Sanborn RE, Zhou C, Tang KJ, Cho BC, Cheng S, Popat S, Ono A, Lu S, Majem M, Aguilar A, Del Rosario Garcia Campelo M, Hayashi H, Lee KY, Lee SH, Delmonte A, Alatorre-Alexander J, Richardson G, Santos V, Dooms C, Sabari JK, Shu CA, Girard N, Mansfield AS, Park K, Xia Y, Bhattacharya A, Buyukkaramikli N, Perualila N, Diels J, Acharya S, Chandler C, Proskorovsky I, Dearden L, Wortman-Vayn H, Mahadevia PJ, Knoblauch RE, Agrawal T, Baig M, Felip E

doi: 10.1007/s11523-025-01182-0

Related content

Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study

Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy

Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study

The Italian ATLAS registry study: Real-world outcomes with adjuvant osimertinib in patients with resected EGFR-mutated NSCLC

Actionable Genomic Alterations in NSCLC: What is Changing in Testing and Treatment?

ADAURA: Adjuvant osimertinib provides OS benefit at eight years in patients with resected EGFR-mutated NSCLC

Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC

Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapy

Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study